Elixir Medical Announces 2-Year Results From the EXCELLA BD Trial on the Desyne BD System



May 24, 2013—Elixir Medical Corporation (Sunnyvale, CA) announced the long-term results of its CE Mark-approved Desyne BD novolimus-eluting coronary stent system with biodegradable polymer coating compared to the control device, the Endeavor zotarolimus-eluting coronary stent system (Medtronic, Inc., Minneapolis, MN) with durable coating, in the EXCELLA BD randomized clinical trial.

At 2 years, device-oriented composite endpoints, a measure of major adverse cardiac events, for Elixir's Desyne were exceptionally low and unchanged from 6 months through 2 years (2.7%). Clinically indicated target lesion revascularization rates at 2 years were also unchanged and were lower in favor of the Desyne BD stent as compared to the control device (1.8% vs 3.2%). There were no reported stent thrombosis events with Desyne BD through 2 years.



“I am excited about the excellent and sustained long-term clinical outcomes demonstrated by Desyne BD through 2 years,” said Ricardo Costa, MD, of Instituto Dante Pazzanese de Cardiologia in Sao Paulo, Brazil, who presented these results at EuroPCR in Paris, France. “The combined attributes of lowest bioabsorbable polymer load and drug dose and thin stent struts provides physicians with a state-of-the-art, next-generation workhorse product that raises the bar for treating patients with coronary artery disease.”